Paper41324239
Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial.
Vajgel G and 7 others. Nephrol Dial Transplant, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial. Papers, record 41324239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41324239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glucosides | Major topic |
| Lupus Nephritis | Major topic |
| Benzhydryl Compounds | Major topic |
| Proteinuria | Major topic |
| Humans | |
| Female | |
| Adult | |
| Male | |
| Glomerular Filtration Rate | |
| Cross-Over Studies | |
| Follow-Up Studies | |
| Middle Aged | |
| Prognosis | |
| Kidney Function Tests |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CNPq | PubMed | |||
| CAPES | PubMed | |||
| FACEPE | PubMed |
Source PubMed
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42951286 | Effect of dapagliflozin on renal response in patients with biopsy-confirmed lupus nephritis receiving stable maintenance immunosuppression and renin-angiotensin system inhibition: protocol for the multicentre randomised DAPA-LN trial. | Lupus Sci Med | 2026 | https://conductscience.org/library/papers/42951286 | PubMed |
| 42940159 | Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Chronic Kidney Disease of Predominantly Glomerular Origin: A Two-Year Comparative Cohort Study with Historical Controls. | Biomedicines | 2026 | https://conductscience.org/library/papers/42940159 | PubMed |
| 42182829 | Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed. | Glomerular Dis | 2026 | https://conductscience.org/library/papers/42182829 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41324239
GET https://conductscience.org/api/papers/v1/41324239/authors